| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/50-1/100 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/5000-1/10000 | Human,Mouse,Rat |
| Aliases | PRSS10 |
| WB Predicted band size | 54 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse |
| Immunogen | Fusion protein of human TMPRSS2 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是关于TMPRSS2抗体的3篇参考文献概览(虚构示例，供参考)：
1. **文献名称**: *"A monoclonal antibody targeting TMPRSS2 effectively blocks SARS-CoV-2 entry in vitro"*
**作者**: Smith A et al.
**摘要**: 研究报道了一种新型单克隆抗体，通过特异性结合TMPRSS2的胞外结构域，抑制其对SARS-CoV-2刺突蛋白的切割，阻断病毒进入人肺上皮细胞，为抗病毒治疗提供潜在策略。
2. **文献名称**: *"Characterization of TMPRSS2-specific antibodies for immunohistochemical detection in prostate cancer tissues"*
**作者**: Lee C et al.
**摘要**: 开发并验证了两种高特异性TMPRSS2抗体，用于前列腺癌组织样本的免疫组化检测，证实其与TMPRSS2-ERG融合蛋白的关联性，为癌症诊断提供工具。
3. **文献名称**: *"TMPRSS2 inhibition by a polyclonal antibody reduces influenza A virus replication in murine models"*
**作者**: Zhang Y et al.
**摘要**: 利用多克隆抗体靶向抑制TMPRSS2的蛋白酶活性，在小鼠模型中显著降低甲型流感病毒的肺内复制，证明TMPRSS2抗体在呼吸道病毒感染中的治疗潜力。
(注：以上文献为模拟内容，实际引用需查询PubMed等数据库获取真实文献。)
**Background of TMPRSS2 Antibodies**
TMPRSS2 (Transmembrane Serine Protease 2) is a cell surface-associated protease belonging to the type II transmembrane serine protease family. It plays a critical role in proteolytic activation of viral envelope proteins, including SARS-CoV-2 spike protein, facilitating viral entry into host cells. TMPRSS2 is also implicated in prostate cancer, where its fusion with the ERG oncogene (TMPRSS2-ERG) is a common driver event.
Antibodies targeting TMPRSS2 are essential tools for studying its expression, localization, and function. They are widely used in research to investigate its role in viral pathogenesis (e.g., COVID-19) and cancer progression. In COVID-19 studies, TMPRSS2 antibodies help evaluate the protease’s interaction with viral proteins and assess therapeutic strategies, such as protease inhibitors. In oncology, these antibodies aid in detecting TMPRSS2-ERG fusion proteins, which are biomarkers for prostate cancer diagnosis and prognosis.
Commercial TMPRSS2 antibodies are typically raised against specific epitopes in its extracellular or cytoplasmic domains. Validation includes testing in applications like Western blotting, immunohistochemistry, and flow cytometry. Cross-reactivity with homologous proteases (e.g., TMPRSS4) must be ruled out to ensure specificity. Recent advancements in monoclonal antibody development have improved target selectivity, supporting both basic research and clinical investigations.
Overall, TMPRSS2 antibodies remain pivotal in unraveling its dual role in infectious diseases and cancer, offering insights for therapeutic targeting and biomarker discovery.
×
